# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in ...